Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'INTERMEDIATE GRADE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 180 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Visco, C; Medeiros, LJ; Mesina, OM; Rodriguez, MA; Hagemeister, FB; McLaughlin, P; Romaguera, JE; Cabanillas, F; Sarris, AH
      Non-Hodgkin's lymphoma affecting the testis: Is it curable with doxorubicin-based therapy?

      CLINICAL LYMPHOMA
    2. Cerhan, JR; Wallace, RB; Dick, F; Kemp, J; Parker, AS; Zheng, W; Sellers, TA; Folsom, AR
      Flood transfusions and risk of non-Hodgkin's lymphoma subtypes and chroniclymphocytic leukemia

      CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
    3. Stein, RS; Greer, JP; Goodman, S; Brandt, SJ; Morgan, D; Macon, WR; McCurley, TL; Wolff, SN
      Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    4. Stein, RS; Greer, JP; Goodman, S; Brandt, SJ; Morgan, DS; Macon, WR; McCurley, TL
      Limited efficacy of intensified preparative regimens and autologous transplantation as salvage therapy in high grade non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    5. Peters, FPJ; Fickers, MMF; Erdkamp, FLG; Wals, J; Wils, JAJM; Schouten, HC
      The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates

      ANNALS OF HEMATOLOGY
    6. Bouabdallah, R; Stoppa, AM; Coso, D; Bardou, VJ; Blaise, D; Chabannon, C; Gastaut, JA; Maraninchi, D
      Clinical outcome after front-line intensive sequential chemotherapy (ISC) in patients with aggressive non-Hodgkin's lymphoma and high-risk international prognostic index (IPI 3): Final analysis of survival in two consecutiveISC trials

      ANNALS OF ONCOLOGY
    7. Nachbaur, D; Oberaigner, W; Fritsch, E; Nussbaumer, W; Gastl, G
      Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single-centre experience

      EUROPEAN JOURNAL OF HAEMATOLOGY
    8. Hagemeister, FB; Donato, M
      Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience

      EUROPEAN JOURNAL OF HAEMATOLOGY
    9. Sarris, AH; Braunschweig, I; Medeiros, LJ; Duvic, M; Ha, CS; Rodriguez, MA; Hagemeister, FB; McLaughlin, P; Romaguera, J; Cox, J; Cabanillas, F
      Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy

      JOURNAL OF CLINICAL ONCOLOGY
    10. Rodriguez, J; Munsell, M; Yazji, S; Hagemeister, FB; Younes, A; Andersson, B; Giralt, S; Gajewski, J; de Lima, M; Couriel, D; Romaguera, J; Cobanillas, FF; Champlin, RE; Khouri, IF
      Impact of high-dose chemotherapy on peripheral T-cell lymphomas

      JOURNAL OF CLINICAL ONCOLOGY
    11. Guglielmi, C; Martelli, M; Federico, M; Zinzani, PL; Vitolo, U; Bellesi, G; Santini, G; Tarella, C; Zallio, F; Pregno, P; Di Renzo, N; Resegotti, L
      Risk assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas

      HAEMATOLOGICA
    12. Krieger, G; Kreysing, E; Kneba, M
      Long-term results with MACOP-B and radiation therapy for aggressive lymphomas

      ONKOLOGIE
    13. Wilder, RB; Rodriguez, MA; Tucker, SL; Ha, CS; Hess, MA; Cabanillas, FF; Cox, JD
      Radiation therapy after a partial response to chop chemotherapy for aggressive lymphomas

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    14. van Besien, K; Rodriguez, A; Tomany, S; Younes, A; Donate, M; Sarris, A; Giralt, S; Mehra, R; Andersson, B; Gajewski, J; Champlin, R; Cabanillas, F
      Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

      BONE MARROW TRANSPLANTATION
    15. Salar, A; Sierra, J; Gandarillas, M; Caballero, MD; Manin, J; Lahuerta, JJ; Garcia-Conde, J; Arranz, R; Leon, A; Zuazu, J; Garcia-Larana, J; Lopez-Guillermo, A; Sanz, MA; Granena, A; Garcia, JC; Conde, E
      Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens

      BONE MARROW TRANSPLANTATION
    16. Olivieri, A; Capelli, D; Montanari, M; Brunori, M; Massidda, D; Poloni, A; Lucesole, M; Centurioni, R; Candela, M; Masia, MC; Tonnini, C; Leoni, P
      Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: A single center experience

      BONE MARROW TRANSPLANTATION
    17. Krol, ADG; Berenschot, HWA; Doekharan, D; Henzen-Logmans, S; van der Holt, B; van 't Veer, MB
      Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy andradiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy

      RADIOTHERAPY AND ONCOLOGY
    18. Page, RD; Romaguera, JE; Osborne, B; Medeiros, LJ; Rodriguez, J; North, L; Sanz-Rodriguez, C; Cabanillas, F
      Primary hepatic lymphoma - Favorable outcome after combination chemotherapy

      CANCER
    19. Wilder, RB; Rodriguez, MA; Ha, CS; Pro, B; Hess, MA; Cabanillas, F; Cox, JD
      Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma

      CANCER
    20. Cortelazzo, S; Rambaldi, A; Rossi, A; Oldani, E; Ghielmin, M; Benedetti, F; Tarella, C; Zaglio, F; Vitolo, U; Di Nicola, M; Pogliani, E; Cavalli, F; Gianni, AM; Barbui, T
      Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma

      BRITISH JOURNAL OF HAEMATOLOGY
    21. Niitsu, N; Okabe-Kado, J; Okamoto, M; Takagi, T; Yoshida, T; Aoki, S; Hirano, M; Honma, Y
      Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma

      BLOOD
    22. Tutschka, PJ; Bilgrami, SA; Feingold, JM; Edwards, RL; Bona, RD; Naqvi, B; Clive, J
      Cytoreduction and stem cell mobilization with a regimen of paclitaxel, etoposide and cyclophosphamide followed by autologous transplantation using a preparative regimen of busulfan, etoposide and cyclophosphamide for patients with advanced lymphoma

      ACTA HAEMATOLOGICA
    23. Kluin-Nelemans, HC; Zagonel, V; Anastasopoulou, A; Bron, D; Roozendaal, KJ; Noordijk, EM; Musson, H; Teodorovic, I; Maes, B; Carbone, A; Carde, P; Thomas, J
      Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study

      JOURNAL OF THE NATIONAL CANCER INSTITUTE
    24. Ezzat, AA; Ibrahim, EM; Stuart, RK; Ajarim, D; Bazarbashi, S; El-Foudeh, MO; Rahal, M; Al-Sayed, A; Berry, J
      Adding high-dose tamoxifen to CHOP does not influence response or survivalin aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial

      MEDICAL ONCOLOGY
    25. Stockerl-Goldstein, KE; Reddy, SA; Horning, SJ; Blume, KG; Chao, NJ; Hu, WW; Johnston, LJ; Long, GD; Strober, S; Wong, RM; Feiner, RH; Kohler, S; Negrin, RS
      Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor"mobilization of peripheral blood progenitor cells

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    26. Leger, CS; Bredeson, C; Kearns, B; Bence-Bruckler, I; Atkins, H; Huebsch, L
      Autologous blood and marrow transplantation in patients 60 years and older

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    27. Intragumtornchai, T; Sutheesophon, J; Sutcharitchan, P; Swasdikul, D
      A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    28. Voog, E; Sebban, C; Biron, P; Philip, T; Blay, JY
      A prospective study of the LMB regimen for diffuse large cell non Hodgkin's lymphoma in adults

      LEUKEMIA & LYMPHOMA
    29. Inoue, R; Natazuka, T; Shimoyama, M; Tamekane, A; Kajimoto, Y; Iwata, N; Matsuoka, H; Chihara, K; Matsui, T
      Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: A pilot study

      LEUKEMIA & LYMPHOMA
    30. Montuoro, A; Lalle, M; Ingletto, D
      Autologous bone marrow transplantation as consolidation therapy in newly diagnosed non-Hodgkin's lymphoma: Long-term outcome

      INTERNATIONAL JOURNAL OF ONCOLOGY
    31. Haioun, C; Besson, C; Lepage, E; Thieblemont, C; Simon, D; Rose, C; Tilly, H; Sonet, A; Lederlin, P; Attal, M; Briere, J; Reyes, F
      Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients

      ANNALS OF ONCOLOGY
    32. Itoh, K; Ohtsu, T; Wakita, H; Igarashi, T; Ishizawa, K; Onozawa, Y; Fujii, H; Minami, H; Sasaki, Y
      Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    33. Cerny, T; Betticher, D
      Role of high-dose therapy in diffuse large B-cell lymphoma

      ANNALS OF ONCOLOGY
    34. Fisher, RI
      Diffuse large-cell lymphoma

      ANNALS OF ONCOLOGY
    35. Linch, DC; Smith, P; Hancock, BW; Hoskin, PJ; Cunningham, DC; Newland, AC; Milligan, D; Stevenson, PA; Wood, JK; Maclennan, KA; Hudson, BV; Hudson, GV; Gregory, WM
      A randomised British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    36. Niitsu, N; Okamoto, M; Kuraishi, Y; Nakamura, S; Kodama, F; Hirano, M
      CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF)for patients with aggressive non-Hodgkin's lymphoma: a pilot study

      EUROPEAN JOURNAL OF HAEMATOLOGY
    37. Dumontet, C; Thieblemont, C; Espinouse, D; Bouafia, F; Hequet, O; Salles, G; Coiffier, B
      A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors

      LEUKEMIA
    38. Tilly, H; Mounier, N; Lederlin, P; Briere, J; Dupriez, B; Sebban, C; Bosly, A; Biron, P; Nouvel, C; Herbrecht, R; Bordessoule, D; Coiffier, B
      Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH87-1 study

      JOURNAL OF CLINICAL ONCOLOGY
    39. Doorduijn, JK; Spruit, PH; Van der Holt, B; Van't Veer, MB; Budel, LM; Lowenberg, B; Sonneveld, P
      Etoposide, mitoxantrone and prednisone, a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma

      HAEMATOLOGICA
    40. Greinix, HT
      Autologous stem-cell transplantation in Hodgkin's and non-Hodgkin's lymphoma

      ACTA MEDICA AUSTRIACA
    41. Andersson, PO; Brune, M; Ekman, T
      Remission inversion and no transplant-related mortality - A single centre experience of autologous stem cell transplantation in malignant lymphoma

      ACTA ONCOLOGICA
    42. Berninger, VW
      Development of language by hand and its connections with language by ear, mouth, and eye

      TOPICS IN LANGUAGE DISORDERS
    43. Stein, RS; Greer, JP; Goodman, S; Brandt, SJ; Morgan, DS; Macon, WR; McCurley, TL; Wolff, SN
      Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma

      BONE MARROW TRANSPLANTATION
    44. Bouabdallah, R; Coso, D; Costello, R; Bardou, VJ; Blaise, D; Xerri, L; Sainty, D; Maraninchi, D; Gastaut, JA
      Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center

      BONE MARROW TRANSPLANTATION
    45. Fisher, RI
      Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma

      SEMINARS IN ONCOLOGY
    46. Armitage, JO
      High-dose chemotherapy and autologous hematopoietic stem cell transplantation: The lymphoma experience and its potential relevance to solid turners

      ONCOLOGY
    47. Arranz, R; Sanz-Rodriguez, C; Pajuelo, FJ; Chamorro, CM; Acevedo, A; Perez, G; Ranada, JMF
      Hematopoietic stem cell transplantation as salvage treatment in patients with aggresive non-Hodgkin's lymphoma

      MEDICINA CLINICA
    48. Molina, A; Krishnan, AY; Nademanee, A; Zabner, R; Sniecinski, I; Zaia, J; Forman, SJ
      High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy

      CANCER
    49. Kewalramani, T; Zelenetz, AD; Hedrick, EE; Donnelly, GB; Hunte, S; Priovolos, AC; Qin, J; Lyons, NC; Yahalom, J; Nimer, SD; Moskowitz, CH
      High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis

      BLOOD
    50. Tarumi, T; Sawada, K; Koizumi, K; Takano, H; Fukada, Y; Nishio, M; Fujie, T; Ohnishi, K; Kohno, M; Sato, N; Sekiguchi, S; Koike, T
      A pilot study of a response oriented chemotherapeutic regimen combined with autologous peripheral blood progenitor cell transplantation in aggressivenon-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    51. Lossos, IS; Paltiel, O; Polliack, A
      Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas

      LEUKEMIA & LYMPHOMA
    52. Salles, G; Coiffier, B
      Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

      BAILLIERES CLINICAL HAEMATOLOGY
    53. Cortelazzo, S; Rossi, A; Bellavita, P; Oldani, E; Viero, P; Buelli, M; Rambaldi, A; Barbui, T
      Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI)

      ANNALS OF ONCOLOGY
    54. Shipp, MA; Abeloff, MD; Antman, KH; Carroll, G; Hagenbeek, A; Loeffler, M; Montserrat, E; Radford, JA; Salles, G; Schmitz, N; Symann, M; Armitage, JO; Coiffier, B; Philip, T
      International Consensus Conference on High-Dose Therapy with HematopoieticStem-Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report ofjury

      ANNALS OF ONCOLOGY
    55. Bierman, PJ
      High-dose therapy with stem-cell transplantation in the malignant lymphomas - The Winter article reviewed

      ONCOLOGY-NEW YORK
    56. Niitsu, N; Sasaki, K; Umeda, M
      A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma

      LEUKEMIA
    57. Plantier-Colcher, I; Dupriez, B; Simon, M; Detourmignies, L; Jouet, JP; Fenaux, P; Bauters, F; Morel, P
      The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases

      LEUKEMIA
    58. Davis, TA; White, CA; Grillo-Lopez, AJ; Velasquez, WS; Link, B; Maloney, DG; Dillman, RO; Williams, ME; Mohrbacher, A; Weaver, R; Dowden, S; Levy, R
      Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:Results of a phase II trial of rituximab

      JOURNAL OF CLINICAL ONCOLOGY
    59. Shipp, MA; Abeloff, MD; Antman, KH; Carroll, G; Hagenbeek, A; Loeffler, M; Montserrat, E; Radford, JA; Salles, G; Schmitz, N; Symann, M; Armitage, JO; Philip, T; Coiffier, B
      International consensus conference on high-dose therapy with hematopoieticstem cell transplantation in aggressive non-hodgkin's lymphomas: Report ofthe jury

      JOURNAL OF CLINICAL ONCOLOGY
    60. Bremnes, RM; Bremnes, Y; Donnem, T
      High-grade non-Hodgkin's lymphoma treated in northern Norway - Treatment, outcome, and prognostic factors

      ACTA ONCOLOGICA
    61. Blystad, AK; Kvalheim, G; Torlakovic, E; Holte, H; Jacobsen, E; Beiske, K; Valerhaugen, H; Lenschow, E; Kvaloy, S
      High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma

      BONE MARROW TRANSPLANTATION
    62. Lee, SM; Ryder, WDJ; Clemons, MJ; Morgenstern, GR; Chang, J; Scarffe, JH; Radford, JA
      Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma

      BONE MARROW TRANSPLANTATION
    63. Moskowitz, CH; Nimer, SD; Glassman, JR; Portlock, CS; Yahalom, J; Straus, DJ; O'Brien, JP; Elkin, N; Bertino, JR; Zelenetz, AD
      The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma

      BONE MARROW TRANSPLANTATION
    64. Dhedin, N; Giraudier, S; Gaulard, P; Esperou, H; Ifrah, N; Michallet, M; Milpied, N; Rio, B; Cahn, JY; Molina, L; Laporte, JL; Guilhot, F; Kuentz, M
      Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database

      BRITISH JOURNAL OF HAEMATOLOGY
    65. Stahel, RA; Jost, LM; Kroner, T; Dommann-Scherrer, C; Maurer, R; Glanzmann, C; Jacky, E; Pichert, G; Pestalozzi, B; Marincek, B; Sauter, C; Honegger, H
      A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remission

      BRITISH JOURNAL OF HAEMATOLOGY
    66. Gordon, LI; Young, M; Weller, E; Habermann, TM; Winter, JN; Glick, J; Ghosh, C; Flynn, P; Cassileth, PA
      A phase II trial of 200% ProMACE-CytaBOM-in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity

      BLOOD
    67. Niitsu, N; Okabe-Kado, J; Kasukabe, T; Yamamoto-Yamaguchi, Y; Umeda, M; Honma, Y
      Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma

      BLOOD
    68. FRIDRIK MA; JAGER G; KIENZER HR; HAUSMANINGER H; OPPITZ P; KRIEGER O; ZABERNIGG A; LANG A; NEUBAUER M; WEIDINGER G; SCHILLER L; SEEWANN HL; CHOTT A; LINKESCH W
      EFFICACY AND TOXICITY OF 2-CHLORODEOXYADENOSINE (CLADRIBINE) - 2 H INFUSION FOR 5 DAYS - AS FIRST-LINE TREATMENT FOR ADVANCED LOW-GRADE NON-HODGKINS-LYMPHOMA

      European journal of cancer
    69. BOUABDALLAH R; XERRI L; BARDOU VJ; STOPPA AM; BLAISE D; SAINTY D; MARANINCHI D; GASTAUT JA
      ROLE OF INDUCTION CHEMOTHERAPY AND BONE-MARROW TRANSPLANTATION IN ADULT LYMPHOBLASTIC LYMPHOMA - A REPORT ON 62 PATIENTS FROM A SINGLE-CENTER

      Annals of oncology
    70. CABANILLAS F; PAVON JRD; HAGEMEISTER FB; MCLAUGHLIN P; RODRIGUEZ MA; ROMAGUERA JE; DONG K; MOON T
      ALTERNATING TRIPLE THERAPY FOR THE TREATMENT OF INTERMEDIATE GRADE AND IMMUNOBLASTIC LYMPHOMA

      Annals of oncology
    71. Celsing, E; Widell, S; Merk, K; Bernell, P; Grimfors, G; Hedlund, A; Liliemark, J; Svedmyr, E; Osby, E; Bjorkholm, M
      Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    72. YALCIN S; KARS A; OZISIK Y; TEKUZMAN G; OZYILKAN O; CELIK I; BARISTA I; GULLU I; GULER N; BALTALI E; FIRAT D
      VB-CHEP CHEMOTHERAPY REGIMEN FOR AGGRESSIVE NON-HODGKINS-LYMPHOMAS

      European journal of haematology
    73. GEISLER CH; HANSEN MM; ANDERSEN NS; BROWN P; CHRISTENSEN LD; DICKMEISS E; ERSBOLL J; MYHRE J; HANSEN M; JUHL BR; MORTENSEN BT; PEDERSENBJERGAARD J
      BEAM-CELL TRANSPLANTATION IN MALIGNANT-LYMPHOMA - 100 CONSECUTIVE TRANSPLANTS IN A SINGLE-CENTER - EFFICACY, TOXICITY AND ENGRAFTMENT IN RELATION TO STEM-CELL SOURCE AND PREVIOUS TREATMENT(AUTOLOGOUS STEM)

      European journal of haematology
    74. GAYNOR ER; FISHER RI
      CHOP THERAPY - HAS SHORTER-COURSE THERAPY HAD AN IMPACT ON LYMPHOMAS

      Cancer investigation
    75. SANTINI G; SALVAGNO L; LEONI P; CHISESI T; DESOUZA C; SERTOLI MR; RUBAGOTTI A; CONGIU AM; CENTURIONI R; OLIVIERI A; TEDESCHI L; VESPIGNANI M; NATI S; SORACCO M; PORCELLINI A; CONTU A; GUARNACCIA C; PESCOSTA N; MAJOLINO I; SPRIANO M; VIMERCATI R; ROSSI E; ZAMBALDI G; MANGONI L; ENDRIZZI L; SILENI VC; MIGGIANO MC; MARINO G; DAMASIO E; RIZZOLI V
      VACOP-B VERSUS VACOP-B PLUS AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ADVANCED DIFFUSE NON-HODGKINS-LYMPHOMA - RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL BY THE NON-HODGKINS-LYMPHOMA COOPERATIVE STUDY-GROUP

      Journal of clinical oncology
    76. POPAT U; PRZEPIORK D; CHAMPLIN R; PUGH W; AMIN K; MEHRA R; RODRIGUEZ J; GIRALT S; ROMAGUERA J; RODRIGUEZ A; PRETI A; ANDERSSON B; KHOURI I; CLAXTON D; DELIMA M; DONATO M; ANDERLINI P; GAJEWSKI J; CABANILLAS F; VANBESIEN K
      HIGH-DOSE CHEMOTHERAPY FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - MEDIASTINAL LOCALIZATION PREDICTS FOR A FAVORABLE OUTCOME

      Journal of clinical oncology
    77. FEDERICO M; CLO V; BURGIATELLI M; CAROTENUTO M; GOBBI PG; VALLISA D; LOMBARDO M; AVANZINI P; DIRENZO N; DINI D; BALDINI L; SILINGARDI V
      EFFICACY OF 2 DIFFERENT PROMACE-CYTABOM DERIVED REGIMENS IN ADVANCED AGGRESSIVE NON-HODGKINS-LYMPHOMA - FINAL REPORT OF A MULTICENTER TRIALCONDUCTED BY GISL

      Haematologica
    78. FANIN R; SILVESTRI F; GEROMIN A; INFANTI L; SPEROTTO A; CERNO M; STOCCHI R; SAVIGNANO C; RINALDI C; DAMIANI D; BACCARANI M
      AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR AGGRESSIVE NON-HODGKINS-LYMPHOMAS IN FIRST COMPLETE OR PARTIAL REMISSION - A RETROSPECTIVE ANALYSIS OF THE OUTCOME OF 52 PATIENTS ACCORDING TO THE AGE-ADJUSTED INTERNATIONAL PROGNOSTIC INDEX

      Bone marrow transplantation
    79. MOREAU P; MILPIED N; VOILLAT L; COLOMBAT P; MAHE B; RAPP MJ; MOREAU A; DUPAS B; BULABOIS CE; JUGEMORINEAU N; HAROUSSEAU JL
      PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION AS FRONT-LINE THERAPY IN PATIENTS AGED 61 TO 65 YEARS - A PILOT-STUDY

      Bone marrow transplantation
    80. van der Maazen, RWM; Noordijk, EM; Thomas, J; Raemaekers, JMM; Meerwaldt, JH
      Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas

      RADIOTHERAPY AND ONCOLOGY
    81. Wylie, JP; Cowan, RA; Deakin, DP
      The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients

      RADIOTHERAPY AND ONCOLOGY
    82. LAPORT GF; WILLIAMS SF
      THE ROLE OF HIGH-DOSE CHEMOTHERAPY IN PATIENTS WITH HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA

      Seminars in oncology
    83. GREIL R
      PROGNOSIS AND MANAGEMENT STRATEGIES OF LYMPHATIC NEOPLASIAS IN THE ELDERLY I - AGGRESSIVE NON-HODGKINS-LYMPHOMAS

      Oncology
    84. LOPEZ A; PALACIO C
      TREATMENT OF AGGRESSIVE NON-HODGKINS-LYMP HOMAS

      Medicina Clinica
    85. SALLOUM E; JILLELLA AP; NADKARNI R; SEROPIAN S; HU GL; DANDREA E; ZELTERMAN D; COOPER DL
      ASSESSMENT OF PULMONARY AND CARDIAC-FUNCTION AFTER HIGH-DOSE CHEMOTHERAPY WITH BEAM AND PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION

      Cancer
    86. MOK TS; STEINBERG J; CHAN AT; YEO WM; HUI P; LEUNG TW; JOHNSON P
      APPLICATION OF THE INTERNATIONAL-PROGNOSTIC-INDEX IN A STUDY OF CHINESE PATIENTS WITH NON-HODGKINS-LYMPHOMA AND A HIGH-INCIDENCE OF PRIMARYEXTRANODAL LYMPHOMA

      Cancer
    87. NAIR R; RAMAKRISHNAN G; NAIR NN; SAIKIA TK; PARIKH PM; JOSHI SR; SOMAN CS; MUKHADAN M; DINSHAW KT; ADVANI SH
      A RANDOMIZED COMPARISON OF THE EFFICACY AND TOXICITY OF EPIRUBICIN AND DOXORUBICIN IN THE TREATMENT OF PATIENTS WITH NON-HODGKINS-LYMPHOMA

      Cancer
    88. SOLALCELIGNY P; COLOMBAT P
      RELATIONSHIPS BETWEEN DOSE OR DOSE INTENS ITY AND EFFICACY OF CHEMOTHERAPY IN ADULT AGGRESSIVE NON-HODGKINS-LYMPHOMAS

      Bulletin du cancer
    89. SEHN LH; ANTIN JH; SHULMAN LN; MAUCH P; ELIAS A; KADIN ME; WHEELER C
      PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE MEDIASTINUM - OUTCOME FOLLOWING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC-CELL TRANSPLANTATION

      Blood
    90. ARMITAGE JO
      THE DEVELOPMENT OF BONE-MARROW TRANSPLANTATION AS A TREATMENT FOR PATIENTS WITH LYMPHOMA - 20TH CHARD-AND-HINDA-ROSENTHAL-FOUNDATION-AWARD-LECTURE

      Clinical cancer research
    91. MUNKER R; YOUNES A; CABANILLAS F; ADREEFF M
      SOLUBLE CD95 IN THE SERUM OF PATIENTS WITH LOW AND INTERMEDIATE GRADEMALIGNANT-LYMPHOMAS - ABSENCE OF PROGNOSTIC CORRELATIONS

      Leukemia & lymphoma
    92. PHILLIPS GL; REECE DE; WOLFF SN; GOLDIE JH
      THE USE OF CONVENTIONAL SALVAGE CHEMOTHERAPY BEFORE DOSE-INTENSIVE CYTOTOXIC THERAPY AND AUTOLOGOUS TRANSPLANTATION FOR AGGRESSIVE-HISTOLOGY LYMPHOMA - A CASE FOR REEVALUATION

      Leukemia & lymphoma
    93. AVILES A; CALVA A; DIAZMAQUEO JC; TALAVERA A; HUERTAGUZMAN J; VASQUEZ E
      DOSE-ESCALATION OF EPIRUBICIN IN THE CEOP-BLEO REGIMEN - A CONTROLLEDCLINICAL-TRIAL COMPARING STANDARD DOSES FOR THE TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA

      Leukemia & lymphoma
    94. ENGERT A; SCHNELL R; KUPPER F; REISER M; ENGELHARD M; WILHELM M; LATHAN B; BALTESENGLER S; WINTERHALTER B; SCHEULEN ME; DEDERICHS B; TESCH H; WORMANN B; DIEHL V
      A PHASE-II STUDY WITH IDARUBICIN, IFOSFAMIDE AND VP-16 (IIVP-16) IN PATIENTS WITH REFRACTORY OR RELAPSED AGGRESSIVE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA

      Leukemia & lymphoma
    95. AVILES A; NAMBO MJ; TALAVERA A; GARCIA EL; HUERTAGUZMAN J; MAQUEO JCD
      EPIRUBICIN (CEOP-BLEO) VERSUS IDAURUBICIN (CIOP-BLEO) IN THE TREATMENT OF ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA - DOSE-ESCALATION STUDIES

      Anti-cancer drugs
    96. FRIDRIK MA; GREIL R; HAUSMANINGER H; KRIEGER O; OPPITZ P; STOGER M; KLOCKER J; NEUBAUER M; HELM W; PONT J; FAZENY B; HUDEC M; SIMONITSCH I; RADASZKIEWICZ T
      RANDOMIZED OPEN-LABEL PHASE-III TRIAL OF CEOP IMVP-DEXA ALTERNATING CHEMOTHERAPY AND FILGRASTIM VERSUS CEOP/IMVP-DEXA ALTERNATING CHEMOTHERAPY FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA (NHL) - A MULTICENTER TRIAL BY THE AUSTRIAN WORKING GROUP FOR MEDICAL TUMOR-THERAPY/

      Annals of hematology
    97. HOSKINS PJ; LE N; GASCOYNE RD; KLASA R; SHENKIER T; OREILLY S; CONNORS JM
      ADVANCED DIFFUSE LARGE-CELL LYMPHOMA TREATED WITH 12-WEEK COMBINATIONCHEMOTHERAPY - NATURAL-HISTORY OF RELAPSE AFTER INITIAL COMPLETE RESPONSE AND PROGNOSTIC VARIABLES DEFINING OUTCOME AFTER RELAPSE

      Annals of oncology
    98. MEERWALDT JH; CARDE P; SOMERS R; THOMAS J; KLUINNELEMANS JC; BRON D; NOORDIJK EM; COSSET JM; BIJNENS L; TEODOROVIC I; HAGENBEEK A
      PERSISTENT IMPROVED RESULTS AFTER ADDING VINCRISTINE AND BLEOMYCIN TOA CYCLOPHOSPHAMIDE HYDROXORUBICIN/VM-26/PREDNISONE COMBINATION (CHVMP) IN STAGE III-IV INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA/

      Annals of oncology
    99. SEBBAN C; PHILIP T
      INDICATIONS FOR BONE-MARROW AUTOGRAFTS IN MALIGNANT NON-HODGKIN LYMPHOMAS

      La Presse medicale
    100. HAIOUN C; LEPAGE E; GISSELBRECHT C; BASTION Y; COIFFIER B; BRICE P; BOSLY A; DUPRIEZ B; NOUVEL C; TILLY H; LEDERLIN P; BIRON P; BRIERE J; GAULARD P; REYES F
      BENEFIT OF AUTOLOGOUS BONE-MARROW TRANSPLANTATION OVER SEQUENTIAL CHEMOTHERAPY IN POOR-RISK AGGRESSIVE NON-HODGKINS-LYMPHOMA - UPDATED RESULTS OF THE PROSPECTIVE-STUDY LNH87-2

      Journal of clinical oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/05/20 alle ore 23:55:15